High Gross MarginA ~72% gross margin indicates the DDS platform has structurally favorable unit economics and high value capture on productized outcomes. Over 2–6 months this supports scalable licensing revenue and favorable profitability potential if development milestones convert to commercial products, cushioning R&D leverage.

Manageable LeverageLow leverage and materially reduced debt provide financial flexibility and lower refinancing risk, enabling the company to pursue partnerships or bridge financing without immediate distress. This durable balance-sheet trait extends runway options while clinical or licensing catalysts are pursued.

Partnership/Licensing Business ModelA business model focused on licensing, milestone payments, and contract R&D is inherently scalable and capital-efficient for a platform company. Durable partner-driven revenue paths can generate non-dilutive cash inflows upon achievement of clinical/regulatory milestones, aligning incentives with pharma collaborators.

Bears Say

Persistent Revenue DeclineMulti-year top-line shrinkage undermines scale and operating leverage, making it harder to absorb fixed R&D and G&A costs. Over months this reduces bargaining power with partners, limits demonstrated commercial traction, and raises the hurdle for returning to sustainable, self-funded growth.

Chronic Cash BurnSustained negative operating and free cash flow force reliance on external financing or milestone receipts, increasing dilution or covenant risk. Over a 2–6 month horizon this constrains discretionary R&D, heightens execution risk for clinical programs, and pressures management to secure deals or capital.

Eroding Equity And Negative ReturnsDeclining equity and a ~-30% ROE reflect cumulative losses that weaken the capital base. Persisting over months, this erodes stakeholder confidence, reduces shock absorption for adverse outcomes, and can raise cost of capital or complicate partnership negotiations as counterparties discount solvency risk.

NanoCarrier Co., Ltd. News

NANO MRNA Advances RUNX1 mRNA Clinical Trial for Osteoarthritis

The latest announcement is out from NanoCarrier Co., Ltd. ( ($JP:4571) ). NANO MRNA Co., Ltd., through its...

5M ago

NanoCarrier Advances mRNA Therapy for Osteoarthritis

NanoCarrier Co., Ltd. ( ($JP:4571) ) has provided an update. NanoCarrier Co., Ltd., through its subsidiary NANO MRNA...

8M ago

3NQ FAQ

What was NanoCarrier Co., Ltd.’s price range in the past 12 months?

NanoCarrier Co., Ltd. lowest stock price was €0.66 and its highest was €1.15 in the past 12 months.

What is NanoCarrier Co., Ltd.’s market cap?

NanoCarrier Co., Ltd.’s market cap is €67.21M.

When is NanoCarrier Co., Ltd.’s upcoming earnings report date?

NanoCarrier Co., Ltd.’s upcoming earnings report date is May 20, 2026 which is in 90 days.

How were NanoCarrier Co., Ltd.’s earnings last quarter?

NanoCarrier Co., Ltd. released its earnings results on Feb 13, 2026. The company reported -€0.016 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.016.

Is NanoCarrier Co., Ltd. overvalued?

According to Wall Street analysts NanoCarrier Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does NanoCarrier Co., Ltd. pay dividends?

NanoCarrier Co., Ltd. does not currently pay dividends.

What is NanoCarrier Co., Ltd.’s EPS estimate?

NanoCarrier Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NanoCarrier Co., Ltd. have?

NanoCarrier Co., Ltd. has 75,374,160 shares outstanding.

What happened to NanoCarrier Co., Ltd.’s price movement after its last earnings report?

NanoCarrier Co., Ltd. reported an EPS of -€0.016 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.614%.

Which hedge fund is a major shareholder of NanoCarrier Co., Ltd.?

Currently, no hedge funds are holding shares in DE:3NQ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NanoCarrier Co., Ltd.

NANO MRNA Co., Ltd. engages in the research, development, and production of pharmaceuticals using micellar nanoparticles technology. The company develops biopharmaceutical products focused on the medication of cancer and other intractable diseases. It also engages in the research, development, manufacture, and sale of anti-cancer drugs based on micellar nanoparticle technology. The company was founded by Kazunori Kataoka, Teruo Okano, and Ichiro Nakatomi on June 14, 1996 and is headquartered in Tokyo, Japan.